Indeed, earlier investigations in lung adenocarcinoma showed that MEG3 overexpression enhanced cisplatin sensitivity through p53-dependent regulation and downregulation of Bcl-XL, supporting the idea that MEG3's apoptotic regulation may vary across tumor contexts but is consistently associated with improved drug responsiveness (Zhang et al., 2023). This evidence concerns the gene TP53 and lung adenocarcinoma.